TRIM8 and metabolic dysfunction-associated steatotic liver disease: Mechanistic studies have revealed that TRIM8 promotes NAFLD/NASH development by direct interaction with and ubiquitination of TGF-β–activated kinase 1 (TAK1), thus promoting TAK1 phosphorylation and the ensuing activation of the JNK/p38 and NF-κB signaling pathways (34).